232 related articles for article (PubMed ID: 7779872)
21. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
[TBL] [Abstract][Full Text] [Related]
22. [In vitro sensitivity tests for yeasts: evaluation of a micromethod].
Rodero LL; Davel GO; Vivot W; Canteros CE; Fernández C
Rev Argent Microbiol; 1995; 27(2):81-9. PubMed ID: 8552761
[TBL] [Abstract][Full Text] [Related]
23. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.
Pinto PM; Weikert-Oliveira Rde C; Lyon JP; Cury VF; Arantes RR; Koga-Ito CY; Resende MA
Microbiol Res; 2008; 163(5):579-85. PubMed ID: 16962755
[TBL] [Abstract][Full Text] [Related]
24. Candidemia and the susceptibility pattern of Candida isolates in blood.
Osoba AO; Al-Mowallad AW; McAlear DE; Hussein BA
Saudi Med J; 2003 Oct; 24(10):1060-3. PubMed ID: 14578968
[TBL] [Abstract][Full Text] [Related]
25. [Genotype, serotype and sensitivity to fluconazole of Candida albicans strains isolated from HIV-positive patients].
Bastide JM; Pujol C; Mallié M; Reynes J
Bull Acad Natl Med; 1999; 183(2):289-302; discussion 302-3. PubMed ID: 10371777
[TBL] [Abstract][Full Text] [Related]
26. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey.
Fadda ME; Podda GS; Pisano MB; Deplano M; Cosentino S
J Prev Med Hyg; 2008 Jun; 49(2):69-74. PubMed ID: 18847180
[TBL] [Abstract][Full Text] [Related]
28. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production.
Tortorano AM; Prigitano A; Biraghi E; Viviani MA;
J Antimicrob Chemother; 2005 Oct; 56(4):777-9. PubMed ID: 16144871
[TBL] [Abstract][Full Text] [Related]
29. Susceptibility to antifungal agents of Candida species isolated from paediatric and adult patients with haematological diseases.
Nawrot U; Nowicka J; Juszczak K; Gusin B
Mycoses; 2005 Nov; 48(6):385-90. PubMed ID: 16262874
[TBL] [Abstract][Full Text] [Related]
30. Candida albicans strain differentiation in complete denture wearers.
Abu-Elteen KH
New Microbiol; 2000 Jul; 23(3):329-37. PubMed ID: 10939048
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility to 5-fluorocytosine, miconazole and amphotericin B of Candida albicans strains isolated from the throat of non-AIDS patients.
Paniagua GL; Monroy E; Negrete E; Vaca S
Rev Latinoam Microbiol; 2002; 44(2):65-8. PubMed ID: 17063773
[TBL] [Abstract][Full Text] [Related]
32. Antifungal drug susceptibility of oral Candida albicans isolates may be associated with apoptotic responses to Amphotericin B.
Yang C; Gong W; Lu J; Zhu X; Qi Q
J Oral Pathol Med; 2010 Feb; 39(2):182-7. PubMed ID: 19656268
[TBL] [Abstract][Full Text] [Related]
33. Comparative in vitro antifungal susceptibility studies with 30 serotype A and B isolates of Candida albicans.
Shadomy S; Shadomy HJ
Diagn Microbiol Infect Dis; 1991; 14(1):21-2. PubMed ID: 2013207
[TBL] [Abstract][Full Text] [Related]
34. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
35. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
36. [Correlation between resistance testing and typing of Candida albicans--isolates from AIDS patients and chronic recurrent oral candidiasis].
Ruhnke M; Tennagen I; Engelmann E
Mycoses; 1994; 37 Suppl 1():60-3. PubMed ID: 7854368
[TBL] [Abstract][Full Text] [Related]
37. In vitro susceptibility of Candida species isolated from blood culture to some antifungal agents.
Citak S; Ozçelik B; Cesur S; Abbasoğlu U
Jpn J Infect Dis; 2005 Feb; 58(1):44-6. PubMed ID: 15728993
[TBL] [Abstract][Full Text] [Related]
38. [Prevalence and sensitivity of Candida albicans in cultures obtained at an oncologic hospital].
Pliego-Castañeda A; Yañez-Viguri A; López-Valle T; Valdés-de la Torre F
Gac Med Mex; 2000; 136(3):193-9. PubMed ID: 10893847
[TBL] [Abstract][Full Text] [Related]
39. [Torulopsis glabrata. Morphologic characteristics, biotyping and sensitivity to isolates of antifungal agents in vitro].
Pospisil J
Cesk Epidemiol Mikrobiol Imunol; 1991 Jan; 40(1):43-8. PubMed ID: 1826472
[TBL] [Abstract][Full Text] [Related]
40. [Distribution of serotypes A and B of Candida albicans in 502 strains isolated from pathological specimens].
Torres-Rodríguez JM; Nicolás MC; Madrenys N; Gallach C
Med Clin (Barc); 1991 Jun; 97(1):1-3. PubMed ID: 1857140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
